Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC models NEWTON, MA, USA I April 03, 2025 I Auron ...